NCT07559201 Theranostic Applications of Radionuclides in Prostate Cancer
| NCT ID | NCT07559201 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Guilin Medical University, China |
| Condition | Prostate Cancer (Diagnosis) |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2026-01-01 |
| Primary Completion | 2029-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2026-01-01 with a primary completion date of 2029-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The objective of the study is to construct a noninvasive approach ACP3 targeted PET/CT to detect tumor lesions in patients with prostate cancer and to compare with PSMA/FDG PET/CT.
Eligibility Criteria
Inclusion Criteria: * Adult patients (aged 18 years or older); * Patients with newly diagnosed, highly suspected recurrence or previously treated metastases of prostate cancer (supporting evidence may include MRI, CT, tumor markers, and pathology report); * Patients who had scheduled both standard-of-care imaging (PSMA/FDG PET/CT) and ACP3 PET/CT scans; * Patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee. Exclusion Criteria: * The inability or unwillingness of the research participant or legal representative to provide written informed consent.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07559201 clinical trial?
This trial is open to male participants only, aged 18 Years or older, studying Prostate Cancer (Diagnosis). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07559201 currently recruiting?
Yes, NCT07559201 is actively recruiting participants. Contact the research team at muxingyu1992@hotmail.com for enrollment information.
Where is the NCT07559201 trial being conducted?
This trial is being conducted at Guilin, China.
Who is sponsoring the NCT07559201 clinical trial?
NCT07559201 is sponsored by Guilin Medical University, China. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.